PRANA Biotechnology Receives $6.8 Million R&D Tax Incentive Refund
MELBOURNE, June 19th, 2015: Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) has today announced that it has received a $6.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
The refund relates to the cost of eligible research and development activities conducted during the 2014 financial year. These funds will be used to further Prana’s development of PBT2 for the treatment of Huntington’s Disease.
Contacts:
Investor Relations
Rebecca Wilson
E: rwilson@buchanwe.com.au
Tp: +61 3 9866 4722
Media
Gavin Lower
E: glower@buchanwe.com.au
Tp: +61 3 9866 4722
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s technology.
For further information please visit the Company’s web site at www.pranabio.com.
Help employers find you! Check out all the jobs and post your resume.
The refund relates to the cost of eligible research and development activities conducted during the 2014 financial year. These funds will be used to further Prana’s development of PBT2 for the treatment of Huntington’s Disease.
Contacts:
Investor Relations
Rebecca Wilson
E: rwilson@buchanwe.com.au
Tp: +61 3 9866 4722
Media
Gavin Lower
E: glower@buchanwe.com.au
Tp: +61 3 9866 4722
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s technology.
For further information please visit the Company’s web site at www.pranabio.com.
Help employers find you! Check out all the jobs and post your resume.